Physician

Deneen Cherry Dicarlo, MD

According to 2025 Medicare claims, Deneen Dicarlo, MD (NPI: 1497847198) practices rheumatology in the San Luis Obispo-Paso Robles, CA market, with the plurality of this provider's patient population coming from San Luis Obispo, CA. This provider's primary affiliated billing organization is RHEUMATOLOGY SERVICES MEDICAL GROUP (NPI: 1265783948; TIN: 460910853) and primary practice location at 93405-5804.

Dicarlo's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 309 traditional Medicare patients, billed 62,315 HCPCS/CPT codes, and received $932,063 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 944 prescription claims across 113 beneficiaries totaling $1,017,724 in drug costs, led by Rinvoq (Upadacitinib). Open Payments data shows 115 records totaling $2,654. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $21,360 to $932,063. Similarly, Part D prescription costs have risen steadily, from $130,960 to $1,017,724. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$487K$973K2015 Medicare payment: $21,360 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $17,735 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $58,618 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $138,750 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $973,279 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $485,275 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $652,987 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $780,200 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $952,012 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $932,063 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
201594324$21,360
201663450$17,735
20171391,753$58,618
20182004,098$138,750
201930649,440$973,279
202028224,979$485,275
202130531,757$652,987
202230041,106$780,200
202330154,322$952,012
202430962,315$932,063

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$513K$1.0M2015 Drug cost: $130,960 (USD; Tot_Drug_Cst)2016 Drug cost: $12,151 (USD; Tot_Drug_Cst)2017 Drug cost: $94,566 (USD; Tot_Drug_Cst)2018 Drug cost: $277,879 (USD; Tot_Drug_Cst)2019 Drug cost: $655,795 (USD; Tot_Drug_Cst)2020 Drug cost: $1,025,100 (USD; Tot_Drug_Cst)2021 Drug cost: $643,401 (USD; Tot_Drug_Cst)2022 Drug cost: $662,495 (USD; Tot_Drug_Cst)2023 Drug cost: $995,059 (USD; Tot_Drug_Cst)2024 Drug cost: $1,017,724 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
201557621$130,960
201644129$12,151
201782463$94,566
2018126904$277,879
20191491,016$655,795
20201411,148$1,025,100
20211271,012$643,401
2022118805$662,495
2023118924$995,059
2024113944$1,017,724

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
96413Administration of chemotherapy into vein, 1 hour or less85241$114
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more173385$91
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more3134$55
J0897Injection, denosumab, 1 mg714,860$20
96372Injection of drug or substance under skin or into muscle105213$12

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
RinvoqUpadacitinib20660$136,644
Xeljanz XrTofacitinib Citrate24720$131,597
Enbrel SureclickEtanercept14392$118,196
Humira PenAdalimumab14392$100,479
XeljanzTofacitinib Citrate11330$62,635

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.115$2,654Amgen Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Deneen Cherry Dicarlo, MD?

Tedicare shows public-source Medicare data for Deneen Cherry Dicarlo, MD (NPI 1497847198), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Deneen Cherry Dicarlo, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Deneen Cherry Dicarlo, MD?

Deneen Cherry Dicarlo, MD is linked to RHEUMATOLOGY SERVICES MEDICAL GROUP (billing NPI 1265783948) in the available physician profile data.

Does Deneen Cherry Dicarlo, MD have Open Payments data?

Deneen Cherry Dicarlo, MD has 115 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.